DOI: 10.1128/AAC.00169-18
Article Information
PubMed
Published By
History
- Received February 14, 2018
- Returned for modification March 8, 2018
- Accepted May 2, 2018
- Published online June 26, 2018.
Copyright & Usage
Copyright © 2018 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (May 14, 2018).
- You are viewing the most recent version of this article.
Author Information
- James A. Karlowskya,b,
- Sibylle H. Loba,
- Krystyna M. Kazmierczaka,
- Katherine Youngc,
- Mary R. Motylc and
- Daniel F. Sahma
- aInternational Health Management Associates, Inc., Schaumburg, Illinois, USA
- bDepartment of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
- cMerck & Co., Inc., Kenilworth, New Jersey, USA
- Address correspondence to Sibylle H. Lob, shlob{at}ihma.com.
Citation Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. 2018. In vitro activity of imipenem-relebactam against clinical isolates of Gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program. Antimicrob Agents Chemother 62:e00169-18. https://doi.org/10.1128/AAC.00169-18.
